Mode
Text Size
Log in / Sign up
N/A N=81 Randomized Single-blind Prevention

Tragus Stimulation to Prevent Atrial Fibrillation After Cardiac Surgery

Atrial Fibrillation

Enrolled (actual)
81
Serious AEs
2.5%
Results posted
Aug 2022
Primary outcome: Primary: Time to the First Episode of Atrial Fibrillation (AF) >30 Seconds — 53.1; 52.2 hours — p=0.60

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Parasym (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Chicago
Primary completion
Jul 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to the First Episode of Atrial Fibrillation (AF) >30 Seconds
53.1; 52.2 0.60
PRIMARY
Number of Participants Hospitalized for >5 Days
25; 22 0.34
SECONDARY
Overall Atrial Fibrillation (AF) Burden
24.7; 27.3 0.54
SECONDARY
Number of Participants With Rate Control Medications Used for AF
17; 12 0.09
SECONDARY
Number of Participants With Antiarrhythmic Used to Treat AF
16; 10 0.16
SECONDARY
Number of Participants With Inotropes Used for Blood Pressure Support During AF
4; 2 0.67
SECONDARY
Number of Participants With Stroke or Transient Ischemic Attack (TIA)
1; 1 1.0
SECONDARY
All-cause Mortality
3; 0 0.12

Summary

Patients undergoing cardiac surgery, specifically a coronary artery bypass graft and/or heart valve replacement surgery, are at a higher risk for post-procedure atrial fibrillation (AF). AF is a condition in which the upper chambers of the heart do not contract normally and results in an irregular heartbeat. Recent studies have shown that tragus stimulation decreases the likelihood of AF in animals and humans. It has also been shown to reduce inflammation which may be related to post-procedure AF. Tragus stimulation involves stimulating a part of the outer ear, called the tragus, by sending a microcurrent through a small alligator clip. It is believed that tragus stimulation can affect the nervous system, which may reduce heart rate and lead to prevention of AF. The purpose of this study is to determine whether tragus stimulation in subjects undergoing cardiac surgery will lead to shorter occurrences, or even prevention, of AF.

Eligibility Criteria

Inclusion Criteria

  • Patients ≥18 years of age, <90 years of age
  • Estimated life expectancy of at least 1 year at the time of enrollment
  • History of sinus rhythm or paroxysmal atrial fibrillation

Exclusion Criteria

  • Patients ≥90 years of age, <18 years
  • Patients with known prior history of persistent or permanent AF
  • Atrial Fibrillation occurrence within the last 24 hours of procedure
  • Urgent or Emergency cases
  • Pregnant patients
  • Patients undergoing the following cardiac procedures: heart transplant, pulmonary thromboendarterectomy, isolated aortic arch procedures, congenital hear disease, ventricular assist device insertion, extracorporeal membrane oxygenation insertion, and surgical AF ablation
  • Antiarrhythmics prior to surgery (Class I and Class III)
  • High degree atrioventricular block requiring temporary pacing
  • Prior maze procedure for the treatment of AF
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03392649). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search